Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

Impel Pharmaceuticals (NASDAQ:IMPL) First Quarter 2023 Results

Key Financial Results

• Revenue: US$4.37m (up 149% from 1Q 2022).
• Net loss: US$30.1m (loss widened by 12% from 1Q 2022).
• US$1.27 loss per share (further deteriorated from US$1.17 loss in 1Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Impel Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 63%.

Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 42% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Impel Pharmaceuticals (3 make us uncomfortable!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.